Company Shares of CytRx Corporation (NASDAQ:CYTR) Drops by -0.44%

CytRx Corporation (NASDAQ:CYTR) : During the past 4 weeks, traders have been relatively bearish on CytRx Corporation (NASDAQ:CYTR), hence the stock is down -4.13% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.7% relative to the S&P 500. The 4-week change in the price of the stock is -2.59% and the stock has fallen -0.44% in the past 1 week.

The company shares have dropped -43.36% from its 1 Year high price. On Jul 16, 2015, the shares registered one year high at $4.20 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $2.47 and the 200 Day Moving Average price is recorded at $2.53.

The stock has recorded a 20-day Moving Average of 1.61% and the 50-Day Moving Average is 13.06%.


CytRx Corporation (NASDAQ:CYTR): stock turned positive on Friday. Though the stock opened at $2.26, the bulls momentum made the stock top out at $2.28 level for the day. The stock recorded a low of $2.21 and closed the trading day at $2.26, in the green by 1.80%. The total traded volume for the day was 1,079,441. The stock had closed at $2.22 in the previous days trading.

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The company is focused on the clinical development of aldoxorubicin, its modified version of a chemotherapeutic agent. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. It consists of (6-Maleimidocaproyl) hydrazine, an acid-sensitive molecule that is conjugated to doxorubicin. Its laboratory in Freiburg, Germany is conducting discovery and translational research to create drug candidates that utilize linker technologies that couple chemotherapeutic agents and proteins either inside the body or externally, and then concentrate drug in tumors.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.